GOG 0214: Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND# 79,610)
Aims: The purpose of this study is to find out whether certain hormones called progestins may play a role in the prevention of ovarian cancer. In this particular study we are looking at a progestin by the name of Levonorgestrel that is regularly used in birth control pills. We know from other studies that birth control pills, which are a combination of the female hormones estrogen and progestin, protect many women from developing ovarian cancer. However, it is unclear how these hormones prevent ovarian cancer.
Diagnosis: Ovarian Cancer
Principal Investigator: Gustavo Rodriguez, MD
IRB Approval Number: EH08-261
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study coordinator Sharon Goldman at 847.570.1173
Open to Enrollment: Yes

ChemoFx® PRO® A Post-Market Data Collection Study Utilizing Physician Reported Outcomes
Aims: The purpose of this study is to collect, analyze and communicate the results of a test call the ChemoFx® PRO Assay. The ChemoFx® PRO Assay is a laboratory test, developed by and performed in the labs of Precision Therapeutics, Inc. ChemoFx® PRO measures a specific patient's tumor response to single or multiple chemotherapy agents. It examines how many cancer cells are killed after exposure to treatment. The test results may help your doctor determine which chemotherapy drugs are likely to be the most or least effective against your particular cancer. This test is not solely a part of this study and you do not have to participate in this study to have the test done. This clinical trial also aims to identify new ways to make the assay better at predicting how future patients’ cancer will respond to different chemotherapy treatments.
Diagnosis: Solid Tumor Malignancies
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH08-306
Sponsor: Precision Therapeutics, Inc.
Contact: Interested patients should contact study coordinator Sharon Goldman at 847.570.1173
Open to Enrollment: Yes

GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Aims: The purpose of this study is to compare the effects of two different treatment in patients with endometrial cancer that has not spread outside of the abdomen. This study also aims to determine if radiation therapy combined with chemotherapy is more effective than chemotherapy alone. Another purpose of this study is to collect tissue and blood samples from patients with advanced endometrial cancer to see if special tests can be used to determine which patients may respond to treatment, or have a better prognosis, and which patients may have side effects. Patients will receive either chemotherapy and radiation for 4 cycles, or chemotherapy alone for 6 cycles.
Diagnosis: Advanced Endometrial Carcinoma
Principal Investigator: Jean Hurteau,MD
IRB Approval Number:EH09-534
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0249:A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/ Carboplatin in Patients with High-Risk, Early Stage Endometrial Cancer
Aims: The purpose of this study is to compare the effects of two different treatment options for patients with Stage I or Stage IIA endometrial cancer who are at high risk to have their cancer return. Patients in this study will either receive external radiation therapy to the pelvic region, which is the standard of care therapy for this disease, or they will receive vaginal cuff brachytherapy an investigational treatment of internal radiation and chemotherapy with drugs paclitaxel and carboplatin.
Diagnosis: Stage I/IIA Endometrial Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH09-346 
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Aims: The purpose of this study is to compare a combination of radiation therapy and weekly treatment of the chemotherapy drug cisplatin to the standard treatment for this type of cancer which is radiation therapy alone. This study will also evaluate the side effects of combining radiation therapy and chemotherapy with cisplatin. 
Diagnosis: Recurrent Endometrial Cancer 
Principal Investigator: Jean Hurteau, MD 
IRB Approval Number: EH09-122
Sponsor: Gynecologic Oncology Group (GOG) 
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698 
Open to Enrollment: Yes 

Amgen 20060517: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Aims: The purpose of this study is to test whether using the investigational drug AMG 386 in combination with PLD (Pegylated Liposomal Doxorubicin, a traditional chemotherapy agent) improves the outcome of treatment, compared to treatment with PLD chemotherapy alone. AMG 386 is designed to stop the growth of blood vessels in cancer tissues and has not been approved by the FDA (Food and Drug Administration). All study subjects will receive traditional PLD therapy, but not all will receive AMG 386.
Diagnosis: Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH11-138
Sponsor: Amgen, Inc.
Contact: Interested patients should contact study coordinator Sharon Goldman at 847.570.1173
Open to Enrollment: No, temporarily closed

GOG 0261: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin vs Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Aims: The purpose of this study is to compare the drugs carboplatin and paclitaxel to standard treatment for uterine and ovarian carcinosarcoma.  The standard treatment consists of paclitaxel plus the drug ifosfamide and a bladder protecting medicine called mesna. Based on results of other clinical trials, researchers think that the combination of carboplatin and paclitaxel may be as effective as the combination of ifosfamide and paclitaxel but with fewer side effects. In this study, patients will get either the combination of paclitaxel and carboplatin or the combination of ifosfamide and mesna plus paclitaxel. All of the medications on this study are FDA-approved for the treatment of ovarian or uterine cancers.
Diagnosis: Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-015
Sponsor: Gynecologic Oncology Group (GOG)
Contact:
Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 229K: A Phase II Evaluation of BIBF 1120 (IND# 113086) in the Treatment of Recurrent or Persistent Endometrial Carcinoma 
Aims: The purpose of this study is to determine the effectiveness of the drug BIBF 1120 in treating endometrial cancer and to determine the types and severity of side effects caused by this treatment. Also, the study would like to assess whether this treatment can extend the survival of patients with recurrent endometrial cancer that is not curative by standard treatment. BIBF 1120 is not an FDA approved drug and therefore its use is investigational.
Diagnosis: Recurrent or Persistent Endometrial Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-176
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

GOG 267: Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer 
Aims: The purpose of this study is to assess the quality of life and needs of women with advanced ovarian cancer, fallopian tube cancer, or peritoneal cancer, as well as the support available to them. Participants will complete questionnaires at 3 time points, which is the primary focus of the study.
Diagnosis: Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-275
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study coordinator Sharon Goldman at 847.570.1173
Open to Enrollment: Yes

UC10-283/NCI-8348: A Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Aims: The purpose of this study is to determine whether the combination of the two investigational drugs, cediranib and olaparib, is an effective treatment in recurrent ovarian, fallopian tube, or primary peritoneal cancer in comparison to treatment with olaparib alone. Current standard treatments used for these types of cancer do not cure the disease and new types of treatments are needed. Cediranib and olaparib are being used in this study as replacements for standard treatment because researchers wish to know whether the combination of these investigational drugs are more or less effective at treating these types of cancer than current standard treatment.
Diagnosis: Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-073
Sponsor: National Cancer Institute (NCI) / Dana-Farber Cancer Institute
Contact: Interested patients should contact study coordinator Sharon Goldman at 847.570.1173
Open to Enrollment: Yes

× Alternate Text